Takeda Pharmaceuticals shares recently climbed to their highest levels in a year, prompting a reappraisal of the stock’s upside. After outperforming peers in the first nine months of the fiscal year, the company’s valuation no longer appears compelling to analysts. As a result, a leading Wall Street firm downgraded its rating on Takeda from Buy to Hold, citing stretched multiples and limited near-term upside despite robust market momentum.

In the third quarter, Takeda delivered adjusted net profit of ¥235 billion, in line with management’s guidance, even as US revenues declined by 9.1%. Gastrointestinal products led international growth with sales rising 12.1%, while vaccine revenues nearly doubled to ¥23.3 billion. Core operating profit jumped 16.1% year-on-year to ¥332.4 billion thanks to disciplined cost control and foreign-exchange tailwinds, offsetting continued generic pressure in the ADHD and neuroscience franchises.

Entyvio continues to drive Takeda’s growth in inflammatory bowel disease, posting mid-single-digit sales gains globally. However, the broader R&D pipeline lacks a clear successor blockbuster, with no late-stage candidates matching Entyvio’s peak sales potential. In the US, persistent weakness in neuroscience and upcoming generic entries constrain near-term catalysts, leaving investors focused on cost discipline and potential M&A to bridge the innovation gap.